European Patent Office

T 0534/07 (CD8 T cells/OXXON THERAPEUTICS) du 25.11.2008

Identifiant européen de la jurisprudence
ECLI:EP:BA:2008:T053407.20081125
Date de la décision
25 novembre 2008
Numéro de l'affaire
T 0534/07
Requête en révision de
-
Numéro de la demande
98928434.4
Classe de la CIB
C12N 15/30
Langue de la procédure
Anglais
Distribution
Non distribuées (D)
Téléchargement
Décision en anglais
Versions JO
Aucun lien JO trouvé
Autres décisions pour cet affaire
-
Résumés pour cette décision
-
Titre de la demande
Reagents for vaccination which generate a CD8 T cell immune response
Nom du demandeur
Oxxon Therapeutics Limited
Nom de l'opposant
Sanofi Pasteur
OXFORD BIOMEDICA (UK) LTD.
Therion Biologics Corporation
POWDERJECT VACCINES INC.
Danisco US Inc
Chambre
3.3.08
Sommaire
-
Mots-clés
Admissibility of appellant II's appeal - (no) - missing statement of grounds
Admissibility of appellant I's appeal - (yes)
Exclusion of representatives - (no) - no legal basis
Novelty - (yes)
Inventive step - (yes)
Sufficiency of disclosure (yes)
Exergue
-
Affaires citantes
-

ORDER

For these reasons it is decided that:

1. The appeal filed by the appellant PowderJect Vaccines Inc. is rejected as inadmissible.

2. The request filed by the appellant Danisco US, Inc. that the patent attorneys of Carpmaels and Ransford be excluded from further representing any of the parties in proceedings relating to the patent-in-suit EP 979 284 is rejected.

3. The decision under appeal is set aside.

4. The case is remitted to the opposition division with the order to maintain the patent with the claims of the main request of 24 October 2008, said claims having been filed as "First Auxiliary Request- amended", and a description and drawings to be adapted thereto.